Jaguar Animal Health, Inc.
JAGX Healthcare Biotechnology
Jaguar Animal Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.5 million, down 1.52% from fiscal 2024. In the quarter to June 2026, revenue fell 58.9%, EPS grew 95.6%, free cash flow grew 13.8% and total debt fell 83.9%, each against the same quarter a year earlier.
Follow JAGX
Jaguar Animal Health, Inc. (JAGX) EV/Sales
As of 16 October 2026, Jaguar Animal Health, Inc. (JAGX) trades at a EV/Sales of −0.1×. Over the past ten years it has ranged from −0.1× (September 2026) to 19,094,185,096,670× (January 2016); the current reading is higher than 0% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.0× | (55.39%) |
| FY2024 | 2.1× | (19.91%) |
| FY2023 | 2.7× | (100.00%) |
| FY2022 | 570,135× | (93.25%) |
| FY2021 | 8,447,888× | (95.74%) |
| FY2020 | 198,201,063× | 62.42% |
| FY2019 | 122,027,887× | (9.52%) |
| FY2018 | 134,870,296× | (99.26%) |
| FY2017 | 18,282,754,420× | (99.81%) |
| FY2016 | 9,661,624,906,853× | (3.07%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.3× | (67.05%) |
| Dec 2025 | 1.0× | 21.51% |
| Sep 2025 | 0.8× | (26.55%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTGN VistaGen Therapeutics, Inc. compare | −5.9× |
| IMRN IMMURON compare | −3.5× |
| JAGX Jaguar Animal Health, Inc. | −0.1× |
| BIVI BioVie Inc. compare | n/m |
| MTVA MetaVia Inc. compare | n/m |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR compare | n/m |
| NKGN NKGen Biotech, Inc. compare | n/m |
| LSTA Lisata Therapeutics, Inc. compare | 0.1× |
| CSCIF COSCIENS Biopharma Inc. compare | 0.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)